News Jul 01, 2025
Porton Selected as a Representative Company in Frost & Sullivan's "2025 China Pharmaceutical CDMO Industry Insight Blue Book"
Recently, Frost & Sullivan released the “2025 China Pharmaceutical CDMO Industry Insight Blue Book”, a comprehensive analysis of the evolution and strategic trajectory of China’s pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector.
News Jun 20, 2025
Porton Shanghai Pudong R&D and Manufacturing Site Has Passed the EU QP Audit
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that its Shanghai Pudong R&D and Manufacturing Site has passed the EU Qualified Person (QP) audit.
News Jun 19, 2025
Porton Shanghai Fengxian Manufacturing Site Has Passed the EU QP Audit
The successful completion of the QP audit is a recognition of the quality management system of Shanghai Fengxian Manufacturing Site, demonstrating Porton's commitment to practicing high standard quality management. It marks that Shanghai Fengxian Manufacturing Site can provide CDMO services for small molecules, peptides and oligonucleotides, proteins and conjugate drugs that meet international standards to global customers.
News Jun 13, 2025
Porton Awarded Gold Medal by EcoVadis, Ranked Among the Top 5% Globally
As a key participant in the global pharmaceutical value chain, Porton is dedicated to embedding sustainability into its corporate strategy and operations.
NewslettersJun 09, 2025
Porton Newsletter - May 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
News Jun 05, 2025
Porton Announces 2030 Sustainability Targets on World Environment Day
June 5, 2025, Chongqing — On the 54th World Environment Day, Porton Pharma Solutions Ltd. (Porton) officially announced its 2030 sustainability targets, highlighting its actions in response to the global sustainable development initiative and determination to transition into a greener future.
News May 26, 2025
Porton Pharma Solutions Celebrates 20 Years of Excellence and Innovation
Two Decades of Industry Expertise, Building Trust with Pharmaceutical Partners
News May 26, 2025
Porton Pharma Solutions Ltd. Conquers Complex POC Project Through Collaborative Innovation
In today's fast-paced biomedical technology landscape, new drug R&D is transitioning from traditional small molecules to new molecular domains, marked by increasingly complex molecular structures.
News May 23, 2025
Porton to Showcase Integrated CDMO Expertise at BOS Basel 2025
BOS Basel 2025, a premier global event for biopharmaceutical outsourcing, will convene industry leaders to address critical challenges in CMC outsourcing for Small Molecules, Biologics, and Novel Therapeutic Entities. Since its inception in Sheffield (2006), BOS Events have evolved into a refined platform featuring four key components, including a dynamic exhibition highlighting innovations from CROs and CMOs worldwide.
